Highland Therapeutics announces initiation of Phase III trial for HLD-200 in pediatric ADHD patients

The study, "A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD-200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder", is expected to be completed in the fourth quarter of 2014.

http://ift.tt/1mQJsVP